UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 7, 2011
Angiotech Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| British Columbia | | 000-30334 | | 98-0226269 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS. Employer Identification No.) |
1618 Station Street Vancouver, BC, Canada V6A 1B6
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (604) 221-7676
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On April 7, 2011, Angiotech Pharmaceuticals, Inc. (“Angiotech”) issued a press release announcing that the Supreme Court of British Columbia (the “Canadian Court”) has issued a sanction order (the “Sanction Order”) approving the Second Amended and Restated Plan of Compromise or Arrangement concerning, affecting and involving Angiotech and certain of its subsidiaries. The Canadian Court issued the Sanction Order in connection with Angiotech’s previously announced creditor protection proceedings pursuant to theCompanies’ Creditors Arrangement Act (Canada). Additionally, Angiotech announced that the United States Bankruptcy Court for the District of Delaware has issued an order, pursuant to Chapter 15 of title 11 of the United States Code, recognizing and giving full force and effect to the Sanction Order in the United States. A copy of Angiotech’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following exhibits are filed herewith:
| | |
Exhibit
Number | | Description |
| |
| 99.1 | | Press Release, dated April 7, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | Angiotech Pharmaceuticals, Inc. |
| | (Registrant) |
| | |
| Dated: April 11, 2011 | | By: | | /s/ William L. Hunter |
| | | | Name: | | William L. Hunter |
| | | | Title: | | President and Chief Executive Officer |
EXHIBIT INDEX
| | |
Exhibit
Number | | Description |
| |
| 99.1 | | Press Release, dated April 7, 2011. |
